Paul Han, MD
Pulmonary Disease · Englewood, NJNPI 1174590558
Payments from drug & device makers
Across 1,131 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$3K
- Intuitive Surgical$2K
- Boehringer Ingelheim$2K
- Genentech USA, Inc.$2K
- Noah Medical Corporation$1K
- plus $14K from 54 others
What the payments were for
- Consulting fees$1,4555%
- Speaking & faculty fees$8753%
- Travel & lodging$1,6366%
- Food & beverage$20,86878%
- Education$2,0418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,097
- XOLAIR$1,455
- FASENRA$1,225
- GALAXY$1,213
- TEZSPIRE$1,083
- DUPIXENT$994
- The Monarch Airway Clearance System$875
- The Vest System Model 105 Home Care$875
- The Vest System 205 Acute Care$875
- BREZTRI$583
- AIRSUPRA$521
- DALVANCE$468
- Inspire$434
- Otezla$230
- FARXIGA$178
- ALIYA SYSTEM$177
- LUMRYZ$150
- VIVAER STYLUS$148
- RHINAER STYLUS$148
- XYWAV$147
How this compares
$26,875 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 157 | $1,939,614 |
| Dupixent PenDupilumab | 115 | $440,340 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 19 | $281,295 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 369 | $271,194 |
| Pirfenidone | 115 | $157,842 |
| NucalaMepolizumab | 12 | $132,056 |
| Breo ElliptaFluticasone/Vilanterol | 274 | $125,122 |
| WakixPitolisant Hcl | 12 | $95,358 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 140 | $77,141 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 96 | $67,827 |
| TezspireTezepelumab-Ekko | 14 | $61,167 |
| EliquisApixaban | 73 | $50,400 |
| XembifyImmune Globulin,gamma(Igg)klhw | 26 | $46,825 |
| OzempicSemaglutide | 34 | $41,591 |
| Spiriva HandihalerTiotropium Bromide | 14 | $20,138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,815 | $1,976,649209 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,508 | $630,682871 claims |
| Insmed, Inc.Arikayce | $934 | $281,29519 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $3,534 | $145,884161 claims |
| Harmony Biosciences LLCWakix | $419 | $95,35812 claims |
| PfizerEliquis | $76 | $50,40073 claims |
| Grifols USA, LLCXembify | $296 | $46,82526 claims |
| Novo NordiskOzempic | $49 | $41,59134 claims |
| MerckBelsomra, Dulera | $276 | $22,72856 claims |
| AbbVieLinzess | $781 | $7,51512 claims |
| Johnson & JohnsonXarelto | $147 | $5,98011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Englewood
- Harris TesherEnglewood$22K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.